Key Points
- Insider Nathan Mata sold 1,000 shares at $155.50 on May 5 for a total of $155,500, cutting his holding by 37.51% to 1,666 shares.
- Belite Bio shares trade near $156 with a 50‑day/200‑day moving average of $166.79/$152.51, a 12‑month range of $56.10–$200.00 and a market cap of $6.24 billion; the company recently beat quarterly EPS estimates (‑$0.38 vs. consensus ‑$0.56) despite negative trailing P/E.
- Analyst sentiment is largely positive (six Buys, one Hold, one Sell) with a consensus price target of $202.33, while institutional ownership remains very low at about 0.53%.
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $155.50, for a total value of $155,500.00. Following the sale, the insider owned 1,666 shares of the company's stock, valued at $259,063. This represents a 37.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Belite Bio Trading Up 1.2%
Shares of Belite Bio stock opened at $156.21 on Thursday. The stock has a 50 day moving average of $166.79 and a 200 day moving average of $152.51. Belite Bio, Inc. Sponsored ADR has a 12 month low of $56.10 and a 12 month high of $200.00. The firm has a market cap of $6.24 billion, a PE ratio of -67.92 and a beta of -1.19.
Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.18. As a group, equities research analysts forecast that Belite Bio, Inc. Sponsored ADR will post -2.2 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Belite Bio
Several institutional investors have recently modified their holdings of BLTE. Caitong International Asset Management Co. Ltd lifted its stake in shares of Belite Bio by 28,200.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company's stock valued at $45,000 after purchasing an additional 282 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Belite Bio by 28.1% in the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company's stock valued at $87,000 after purchasing an additional 257 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Belite Bio during the 4th quarter worth approximately $103,000. Persistent Asset Partners Ltd bought a new stake in shares of Belite Bio during the 4th quarter worth approximately $108,000. Finally, EverSource Wealth Advisors LLC bought a new stake in shares of Belite Bio during the 2nd quarter worth approximately $147,000. 0.53% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on BLTE. Bank of America began coverage on Belite Bio in a research note on Monday, January 26th. They set a "buy" rating and a $195.00 price target for the company. Benchmark reaffirmed a "buy" rating on shares of Belite Bio in a research note on Tuesday, March 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Belite Bio in a research note on Tuesday, April 7th. Morgan Stanley raised their price objective on Belite Bio from $191.00 to $201.00 and gave the company an "overweight" rating in a research note on Tuesday, March 3rd. Finally, Needham & Company LLC set a $217.00 price objective on Belite Bio in a research note on Tuesday, March 3rd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $202.33.
View Our Latest Stock Report on BLTE
About Belite Bio
(
Get Free Report)
Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.
Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
